Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 21 to 30 of 41

TitleReference numberPublishedLast updated
Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancerTA639
Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancerTA632
Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumabTA612
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancerTA569
Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerTA563
Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimenTA515
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancerTA509
Intrabeam radiotherapy system for adjuvant treatment of early breast cancerTA501
Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancerTA503
Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerTA495

Results per page

  1. 10
  2. 25
  3. 50
  4. All